POP-OUT | CLOSE
 
 
MONTELUKAST
 
MTK is found in 1 entries
MTK
  •   Chemical Component Summary   Hide
    Name MONTELUKAST
    Identifiers 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]ethanoic acid
    Formula C35 H36 Cl N O3 S
    Molecular Weight 586.18 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key UCHDWCPVSPXUMX-TZIWLTJVSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00471   (Stereoisomeric match)
    Name Montelukast
    Groups approved
    Description Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. It is usually administered orally. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Again because of its very specific locus of operation, it does not interact with other allergy medications such as theophylline. Montelukast is marketed in United States and many other countries by Merck & Co. with the brand name Singulair®. It is available as oral tablets, chewable tablets, and oral granules. In India and other countries, it is also marketed under the brand name Montair®, produced by Indian company Cipla.
    Brand names
    • Montair
    • Singulair
    • Singular
    Affected organism Humans and other mammals
    Indication For the treatment of asthma
    Pharmacology Montelukast, like zafirlukast, is a leukotriene receptor antagonist used as an alternative to anti-inflammatory medications in the management and chronic treatment of asthma and exercise-induced bronchospasm (EIB). Unlike zafirlukast, montelukast does not inhibit CYP2C9 or CYP3A4 and is, therefore, not expected to affect the hepatic clearance of drugs metabolized by these enzymes.
    Mechanism of action Montelukast selectively antagonizes leukotriene D<sub>4</sub> (LTD<sub>4</sub>) at the cysteinyl leukotriene receptor, CysLT<sub>1</sub>, in the human airway. Montelukast inhibits the actions of LTD<sub>4</sub> at the CysLT<sub>1</sub> receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
    Route of administration Oral
    Categories
    • Anti-Asthmatic Agents
    • Antiarrhythmic Agents
    • Leukotriene Antagonists
    ATC-Code R03DC03
    AHFS-Code 48:10.24
    CAS number 158966-92-8
    Targets
    Name Sequence search Pharmacological action Actions
    Cysteinyl leukotriene receptor 1   Search  yes antagonist
    Arachidonate 5-lipoxygenase   Search  unknown other/unknown
     
Ligand Image